This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vaccine Hopes Push Markets To Frothy Levels: Stocks To Watch
by Daniel Laboe
There is now a more defined light at the end of this pandemic tunnel. Still, we are not out of the woods yet.
Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates
by Zacks Equity Research
Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.
Novavax (NVAX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -236.02% and -32.94%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.
Novavax (NVAX) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?
by Zacks Equity Research
During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.
Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More
by Zacks Equity Research
Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $93.13 in the latest trading session, marking a -0.49% move from the prior day.
Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M
by Zacks Equity Research
Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $111.42 in the latest trading session, marking a -0.3% move from the prior day.
Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study
by Zacks Equity Research
Vaxart (VXRT) doses the first subject in an early-stage study of its oral coronavirus vaccine candidate VXA-CoV2-1. Stock rises.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $111.02, marking a +0.93% move from the previous day.
Small-Caps, Energy Win the Trading Day
by Mark Vickery
The Energy sector was one of the biggest winners on the day, coming after weeks of hard-hit commodity prices finally getting a little traction.
Biotech Stock Roundup: REGN's Cocktail Data, GILD's RA Drug Approval & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $108.35 in the latest trading session, marking a +0.37% move from the prior day.
CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.
Endo Up on COVID-19 Vaccine Manufacturing Deal with Novavax
by Zacks Equity Research
Endo (ENDP) and Novavax enter a manufacturing agreement for the latter's COVID-19 vaccine candidate, NVX-CoV2373.
Company News for Sep 28, 2020
by Zacks Equity Research
Companies In The News Are: TCOM, BA, NVAX, HON.
Keysight, Mesa, Costco and Novavax as Zacks Bull and Bear of the Day
by Zacks Equity Research
Keysight, Mesa, Costco and Novavax as Zacks Bull and Bear of the Day
Novavax Begins Phase III Study on Coronavirus Vaccine in the UK
by Zacks Equity Research
Novavax (NVAX) starts a phase III efficacy study on its COVID-19 vaccine candidate NVX-CoV2373 in the United Kingdom. Stock rises in after-hours trading.
Rollercoaster Market for Thursday
by Mark Vickery
The major indexes gained less than 1% in total Thursday: +0.37% on the Nasdaq, +0.30% on the S&P 500, +0.20% on the Dow and +0.02% for the Russell 2000.
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
4 Biotechs That Have More Than Doubled Thanks to Coronavirus
by Kinjel Shah
Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $110.15, moving +1.65% from the previous trading session.
Novavax Expands Coronavirus Vaccine Manufacturing Deal in India
by Zacks Equity Research
Novavax (NVAX) amends its present contract with Serum Institute of India Private Limited to widen the manufacturing capacity of its COVID-19 vaccine candidate NVX-CoV2373 to 2 billion plus doses in 2021.